5-ALA (5-Aminolevulinic Acid)

Think of haem production as a factory assembly line, and 5-ALA as the very first raw part that's fed in. Supplement-sellers reason that adding more of that first part means more finished product — more cellular energy. Maybe, modestly. But here's the twist: the exact same molecule has a proven, brilliant job in hospitals as a highlighter pen for surgeons — cancer cells drink it up and glow red so tumours can be cut out cleanly. People buy the highlighter pen hoping it'll work like an energy drink. It's the same ink; that doesn't mean it does the second job.

5-ALA is the first committed intermediate of the haem biosynthetic pathway. Normally its production by ALA synthase is the rate-limiting step; supplying 5-ALA orally (typically with an iron source such as sodium ferrous citrate, because the final step needs ferrous iron) is thought to push more flux down the pathway toward protoporphyrin IX and then haem. More haem means more functional cytochromes for the mitochondrial respiratory chain — hence the claimed boost to cellular energy metabolism and glucose handling. 5-ALA is also reported to induce haem oxygenase-1, an antioxidant/anti-inflammatory enzyme. In its licensed surgical use, the mechanism is different and well-established: tumour cells preferentially accumulate the fluorescent intermediate protoporphyrin IX, which glows red under blue light, marking out cancer tissue.

Research contexts. Not proven uses, and not recommendations.

Two very different bodies of human evidence sit under the same name. The licensed medicinal form (5-ALA hydrochloride) has robust human data for what it's approved to do: as Gliolan it improves the extent of brain-tumour resection by making malignant tissue fluoresce, and topical formulations are established for photodynamic treatment of actinic keratosis. For the supplement uses that put it in the longevity bucket, the evidence is much weaker. The best human signal is on blood sugar: randomised, placebo-controlled trials (largely from Japan) report that 5-ALA phosphate plus sodium ferrous citrate modestly lowers fasting and post-meal glucose in prediabetic and type 2 diabetic adults, with a good safety profile and a randomised dose-escalation safety study in type 2 diabetes. Beyond glycaemia, human studies are small and inconsistent: a 24-week single-arm pilot in maternally inherited diabetes and deafness found only a non-significant trend in insulin secretion, and a Phase II randomised COVID-19 trial failed to improve viral load or symptom scores. Claims about energy, anti-ageing and athletic performance rest mostly on mechanism, animal work and small studies (for example a 14-person crossover on redox balance and aerobic capacity) rather than convincing human trials.

• !Photosensitivity is the standout risk: 5-ALA makes skin and eyes temporarily hypersensitive to light, so light exposure after dosing can cause burns — this is dose-dependent and well documented for the medicinal form (the Gliolan SmPC mandates avoiding strong light and direct sunlight for 24 hours).
• !Two products, one name: the licensed prescription drug (5-ALA hydrochloride) and the food-grade supplement (5-ALA phosphate) are not interchangeable, and the drug's strong evidence does not transfer to the supplement's marketing claims.
• !It is pushed for people with diabetes/prediabetes, where it could interact additively with blood-sugar-lowering medicines — a setting that needs medical oversight, not self-experiment.
• !Most of the supportive RCTs are small, single-region (Japan) and frequently industry-linked, with modest effect sizes; independent replication is limited.
• !Theoretical concern in anyone with a porphyria or haem-pathway enzyme deficiency, where loading the pathway with its precursor could be harmful.
• !Supplement-grade products have variable quality and purity outside regulated channels.

Split status. As a medicine, 5-aminolevulinic acid hydrochloride is licensed in the UK — Gliolan (oral, for fluorescence-guided glioma surgery) holds a marketing authorisation, and topical 5-ALA products are used in dermatology; these are prescription-only and supplied through the NHS/specialists, with side-effects reportable to the MHRA Yellow Card scheme. As a supplement, 5-ALA (usually the phosphate salt with iron) is sold widely in Japan and online as a food/dietary supplement, but it has no UK medicines authorisation for any energy, metabolic or anti-ageing indication. Selling it in the UK with disease or treatment claims would bring it under medicines law (Human Medicines Regulations 2012) and MHRA oversight; marketed purely as a food supplement it falls under food rather than medicines rules. Buying unlicensed 5-ALA online to self-treat conditions like diabetes is outside any regulated, evidence-checked pathway.

• · Phase II· Completed

  Randomised, placebo-controlled trials of oral 5-ALA phosphate/iron on glucose metabolism in prediabetes and type 2 diabetes

  Part of the prediabetes/dysglycaemia evidence base; mostly Japanese, modest effects.

• · Phase II· Completed

  Randomised exploratory Phase II trial of 5-ALA phosphate/iron in mild-to-moderate COVID-19 (PMID 37653769)

  Did not meet primary endpoints (no significant effect on viral load or symptom score).

• · Interventional· Licensed use

  5-ALA (Gliolan) fluorescence-guided resection in high-grade gliomas

  Concerns the licensed surgical/diagnostic use, not the supplement claims.

1. 01
   Therapeutic potential of 5-aminolevulinic acid in metabolic disorders: Current insights and future directions — Kuryata O et al., iScience (2024)

   Recent review summarising 5-ALA's role in haem synthesis, mitochondrial/HO-1 mechanisms and the human metabolic-disorder evidence base.

2. 02
   5-aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects — Higashikawa F et al., Nutrition (2013)

   Human study reporting a glucose-lowering effect; representative of the prediabetes RCT signal.

3. 03
   Pilot Trial on the Effect of 5-Aminolevulinic Acid on Glucose Tolerance in Patients with Maternally Inherited Diabetes and Deafness — Nakamura Y, Haraguchi A, Horie I, Kawakami A, Abiru N, Diabetes Therapy (2023)

   24-week single-arm pilot in mitochondrial diabetes; insulin-secretion trend was non-significant — illustrates how thin the non-glycaemic human data are.

4. 04
   Safety and efficacy of 5-aminolevulinic acid phosphate/iron in mild-to-moderate coronavirus disease 2019: A randomized exploratory phase II trial — Phase II randomized trial, Japan, Medicine (Baltimore) (2023)

   RCT (n=50) that did NOT improve viral load or clinical symptom scores; a useful negative result against over-claiming.

5. 05
   The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain — Al-Saber A et al., Journal of Diabetes Research (2016)

   Randomised, placebo-controlled dose-escalation safety study alongside oral hypoglycaemics; supports tolerability claims. (PMC5055962.)

6. 06
   Gliolan 30mg/ml powder for oral solution — Summary of Product Characteristics (SmPC) — Photonamic / electronic medicines compendium, emc (medicines.org.uk) (2024)

   UK licensing reference for the medicinal form (fluorescence-guided glioma surgery); documents photosensitivity warnings and 24-hour light-avoidance requirement.

7. 07
   The Impact of 5-Aminolevulinic Acid Supplementation on Redox Balance and Aerobic Capacity — Saga N et al., International Journal of Molecular Sciences (2024)

   Small (n=14) double-blind placebo-controlled crossover on redox balance and aerobic capacity — early, limited evidence for the performance claims.